Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein

Bordoloi, Devivasha; Xu, Ziyang; Ho, Michelle; Purwar, Mansi; Bhojnagarwala, Pratik; Cassel, Joel; Giron, Leila B.; Walker, Susanne; Kulkarni, Abhijeet J; Ruiz, Edgar Tello; Choi, Jihae; Zaidi, Faraz I.; Wu, Yuanhan; Wang, Shaoying; Patel, Ami; Ramos, Stephanie; Smith, Trevor; Kulp, Daniel; Ugen, Kenneth E.; Srinivasan, Alagarsamy; Abdel-Mohsen, Mohamed; Humeau, Laurent; Weiner, David B.; Muthumani, Kar

[Image: see text] Coronavirus disease 2019 (COVID-19) is caused by the newly emerged human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the highly contagious nature of SARS-CoV-2, it has infected more than 137 million individuals and caused more than 2.9 million deaths globally as of April 13, 2021. There is an urgent need to develop effective novel therapeutic strategies to treat or prevent this infection. Toward this goal, we focused on the development of monoclonal antibodies (mAbs) directed against the SARS-CoV-2 spike glycoprotein (SARS-CoV-2 Spike) present on the surface of virus particles as well as virus-infected cells. We isolated anti-SARS-CoV-2 Spike mAbs from animals immunized with a DNA vaccine. We then selected a highly potent set of mAbs against SARS-CoV-2 Spike protein and evaluated each candidate for their expression, target binding affinity, and neutralization potential using complementary ACE2-blocking and pseudovirus neutralization assays. We identified a total of 10 antibodies, which specifically and strongly bound to SARS-CoV-2 Spike, blocked the receptor binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) interaction, and neutralized SARS-CoV-2. Furthermore, the glycomic profile of the antibodies suggested that they have high Fc-mediated effector functions. These antibodies should be further investigated for elucidating the neutralizing epitopes on Spike for the design of next-generation vaccines and for their potential in diagnostic as well as therapeutic utilities against SARS-CoV-2.